Table 2 All-cause mortality and CSF culture sterility in the three treatment groups
|  | No. of patients % (95% CI), by regimen | Hazard Ratio, % (95% CI)†| |||||||
|---|---|---|---|---|---|---|---|---|---|
Outcomes | Group 1, AmB-D + 5FC (N = 78) | Group 2, VCZ + 5FC (N = 28) | Group 3, AmB-D + Flu (N = 50) | Group 2 vs Group 1 | p- value | Group 3 vs. Group 1 | p- value | Group 2 vs. Group 3 | p- value |
Mortality at 10Â week No. of deaths % (95% CI) | 8 10.3 (3.5 to 17.0) | 4 14.3 (1.3 to 27.2) | 14 28.0 (15.6 to 40.4) | 1.4 (0.4 to 4.6) | 0.582 | 1.8 (1.1 to 2.7) | 0.008 | 2.2 (0.7 to 6.8) | 0.142 |
Mortality at 2 weeks No. of deaths % (95% CI) | 2 2.6 (− 0.9 to 6.1) | 1 3.6 (− 3.3 to 10.4) | 4 8.0 (0.5 to 15.5) | 1.4 (0.1 to 15.2) | 0.791 | 1.8 (0.8 to 4.2) | 0.156 | 2.3 (0.3 to 20.9) | 0.435 |
Mortality at 4 weeks No. of deaths % (95% CI) | 4 5.1 (0.2 to 10) | 1 3.6 (− 3.3 to 10.4) | 8 16.0 (5.8 to 26.2) | 0.7 (0.1 to 6.3) | 0.747 | 1.8 (1.0 to 3.3) | 0.039 | 4.7 (0.6 to 37.9) | 0.105 |
|  | Treatment difference, % (95% CI)‡ | ||||||||
CSF culture negative at 2 weeks No. of patients % (95% CI) | 38 57.6 (45.7 to 69.5) | 13 48.1 (29.3 to 67.0) | 17 34.0 (20.9 to 47.1) | − 7.6 (− 31.9 to 12.9) | 0.407 | − 23.6 (− 41.3 to − 5.8) | 0.012 | 14.1 (− 8.8 to 37.1) | 0.224 |
CSF culture negative at 10 weeks No. of patients % (95% CI) | 58 87.9 (80.0 to 95.8) | 21 77.8 (62.1 to 93.5) | 35 70 (57.3 to 82.7) | − 10.1 (− 27.6 to 7.4) | 0.221* | − 17.8 (− 32.8 to − 2.9) | 0.017 | 7.8 (12.4 to 30.0) | 0.465 |